Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Assets Average (2017 - 2025)

Historic Assets Average for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $709.8 million.

  • Protagonist Therapeutics' Assets Average rose 1651.3% to $709.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $709.8 million, marking a year-over-year increase of 1651.3%. This contributed to the annual value of $551.3 million for FY2024, which is 8199.61% up from last year.
  • As of Q3 2025, Protagonist Therapeutics' Assets Average stood at $709.8 million, which was up 1651.3% from $730.1 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Assets Average ranged from a high of $743.4 million in Q1 2025 and a low of $243.9 million during Q1 2023
  • In the last 5 years, Protagonist Therapeutics' Assets Average had a median value of $351.2 million in 2021 and averaged $443.5 million.
  • As far as peak fluctuations go, Protagonist Therapeutics' Assets Average plummeted by 2991.49% in 2023, and later skyrocketed by 12199.75% in 2024.
  • Over the past 5 years, Protagonist Therapeutics' Assets Average (Quarter) stood at $360.4 million in 2021, then fell by 26.46% to $265.1 million in 2022, then rose by 29.78% to $344.0 million in 2023, then soared by 96.02% to $674.3 million in 2024, then increased by 5.27% to $709.8 million in 2025.
  • Its Assets Average was $709.8 million in Q3 2025, compared to $730.1 million in Q2 2025 and $743.4 million in Q1 2025.